Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:08 PM ET 8-K
Financial Results Evommune, Inc. EVMN

Evommune Financial Results

Evommune, Inc. reported financial results for the third quarter ended September 30, 2026, and provided a business update on its immunology pipeline. The company highlighted the in-licensing of EVO570, positive Phase 2a data for EVO301 in atopic dermatitis, and confirmed a cash runway extending into the second half of 2029.

“We have built a portfolio of differentiated immunology assets spanning biologics and small molecules, each aimed at a distinct upstream driver of chronic inflammation. The in-licensing of EVO570 expands our reach into T- and B-cell-driven autoimmune diseases, while the EADV data strengthen our conviction that EVO301 has the potential to become a foundational therapy in atopic dermatitis, if approved.”

Luis Peña, President and Chief Executive Officer

“As we advance EVO301 into Phase 2b and expand into ulcerative colitis, 2027 will be a year of execution and clinical catalysts for Evommune, with additional new clinical studies across EVO646 and EVO570 and Phase 2b migraine top-line data expected from EVO756. With a strong balance sheet and an experienced team, we believe we are well positioned to deliver on these milestones and create meaningful value for patients and stockholders.”

Luis Peña, President and Chief Executive Officer
4:08 PM ET 10-Q
Financial Results Airo Group Holdings, Inc. AIRO

Airo Group Holdings Q3 2026 Results: Net Loss of $12M, Loss Widens

AIRO Group Holdings reported revenue of $69.6 million for the nine months ended September 30, 2026, a significant increase from $42.6 million in the prior year period. Despite higher gross profits, the company incurred a net loss of $29.4 million due to increased research and development and general administrative expenses.

Key figure
Net loss $12M
4:08 PM ET 10-Q
Financial Results BioCardia, Inc. BCDA ▶ Call

BioCardia Q3 2026 Results: Net Loss of $1.82M, Loss Widens

BioCardia, Inc. reported a net loss of $5.7 million for the nine months ended September 30, 2026, compared to a $6.2 million loss in the prior year period. The company ended the quarter with $2.2 million in cash and cash equivalents, supported by $5.3 million in proceeds from common stock sales during the year.

Key figure
Net loss $1.82M
4:08 PM ET 10-Q
Financial Results Cyngn Inc. CYN

Cyngn Q3 2026 Results: Net Loss of $5.96M, Loss Narrows

Cyngn Inc. reported a net loss of $18.8 million for the nine months ended September 30, 2026, compared to $17.8 million in the prior year period, despite a significant increase in revenue to $405,527. The company strengthened its cash position through $17.9 million in financing activities, including at-the-market and public stock offerings, ending the period with $3.1 million in cash and $31.8 million in short-term investments.

Key figure
Net loss $5.96M
4:08 PM ET 10-Q
Financial Results Knightscope, Inc. KSCP

Knightscope Q3 2026 Results: Net Loss of $11.8M, Loss Widens

Knightscope, Inc. reported a significant decrease in cash and cash equivalents from $20.6 million at the end of 2025 to $6.8 million as of September 30, 2026. The company's total assets increased to $52.2 million, primarily driven by a substantial rise in goodwill and intangible assets following acquisitions, while management expressed substantial doubt about the company's ability to continue as a going concern.

Key figure
Net loss $11.8M
4:08 PM ET 10-Q
Financial Results United States Antimony Corp UAMY ▶ Call

United States Antimony Q3 2026 Results: Net Loss of $9.53M, Loss Widens

United States Antimony Corp reported a significant increase in net loss to $20.7 million for the nine months ended September 30, 2026, compared to $4.1 million in the prior year, driven by a sharp rise in operating expenses and mineral exploration costs. Despite the loss, the company strengthened its balance sheet through common stock issuances, ending the period with $171.9 million in total stockholders' equity.

Key figure
Net loss $9.53M
4:08 PM ET 10-Q
Financial Results Relmada Therapeutics, Inc. RLMD

Relmada Therapeutics Q3 2026 Results: Net Loss of $13.9M, Loss Widens

Relmada Therapeutics reported a net loss of $45.8 million for the nine months ended September 30, 2026, compared to $37.5 million in the prior year, driven by increased research and development costs. The company significantly strengthened its balance sheet through common stock issuances, ending the period with $202.1 million in cash and short-term investments.

Key figure
Net loss $13.9M
4:08 PM ET 8-K
Financial Results Cisco Systems, Inc. CSCO

Cisco Systems Financial Results

Cisco reported record first quarter fiscal 2027 revenue of $18.5 billion, a 24% increase year-over-year, driven by high demand for AI infrastructure and networking technology. The company raised its full-year fiscal 2027 revenue guidance to a range of $74.8 billion to $75.8 billion and increased its AI infrastructure revenue expectations from hyperscalers to $9 billion.

Term
Q1 2027

“In Q1, we delivered the strongest revenue and non-GAAP earnings per share growth rates for Cisco in over 15 years. Organizations are turning to Cisco for our trusted, market-defining technology and our expertise to help them scale, secure and optimize their environments for the agentic AI era. We are in the very early stages of a multi-year networking supercycle, and we're confident in our ability to continue capturing the multi-billion-dollar opportunity it represents for Cisco.”

Chuck Robbins, chair and CEO of Cisco

“Q1 FY27 was another record quarter for Cisco, with revenue, non-GAAP operating margin, and non-GAAP EPS all exceeding the high end of our guidance ranges. The strength of our Q1 performance gives us confidence to raise our revenue and non-GAAP EPS guidance for FY27. As our business continues to scale, we are unlocking significant operating leverage which is enabling us to grow earnings much faster than revenue. Looking ahead, we remain focused on delivering durable growth and driving continued capital returns.”

Mark Patterson, CFO of Cisco
4:08 PM ET 10-Q
Financial Results Vuzix Corp VUZI ▶ Call

Vuzix Q3 2026 Results: Net Loss of $8.39M, Loss Widens

Vuzix Corp reported total sales of $0.7 million for the quarter ended September 30, 2026, down from $1.2 million in the prior year period. The company experienced a net loss of $8.4 million for the quarter and $23.1 million for the first nine months of 2026, while maintaining a cash balance of $9.2 million.

Key figure
Net loss $8.39M
4:08 PM ET 10-Q
Financial Results AmpliTech Group, Inc. AMPG

AmpliTech Group Q3 2026 Results: Net Loss of $1.89M, Loss Widens

AmpliTech Group reported a net loss of $6.5 million for the nine months ended September 30, 2026, compared to a $3.8 million loss in the prior year period. Despite a slight decrease in nine-month revenue, the company significantly strengthened its balance sheet, increasing cash and marketable securities to over $30 million following successful rights and direct offerings.

Key figure
Net loss $1.89M
4:08 PM ET 10-Q
Financial Results EyePoint, Inc. EYPT ▶ Call

EyePoint Q3 2026 Results: Net Loss of $95.6M, Loss Widens

EyePoint, Inc. reported a significant increase in net loss to $274.9 million for the nine months ended September 30, 2026, driven primarily by a surge in research and development expenses to $237.4 million. Total revenues declined sharply from $30.8 million to $2.0 million year-over-year, largely due to the absence of significant license and collaboration revenue seen in 2025.

Key figure
Net loss $95.6M
4:08 PM ET 10-Q
Financial Results Rocket Pharmaceuticals, Inc. RCKT

Rocket Pharmaceuticals Q3 2026 Results: Net Loss of $49.2M, Loss Narrows

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on genetic medicines for rare diseases. As of September 30, 2026, the company is classified as a non-accelerated filer and smaller reporting company with 111,660,283 shares of common stock outstanding.

Key figure
Net loss $49.2M
4:08 PM ET 8-K
Financial Results HireQuest, Inc. HQI

HireQuest Financial Results

HireQuest reported third quarter 2026 financial results, with total revenue increasing 4.0% to $8.8 million. Net income decreased to $1.7 million, or $0.12 per diluted share, primarily due to a $1.3 million write-down of notes receivable related to the repossession of a franchised location.

Term
Q3 2026

“Our third quarter results reflect continued momentum across our core commercial staffing brands, as improving demand delivered another quarter of year-over-year revenue growth. Our franchise model continues to demonstrate its resilience, allowing us to grow alongside our franchisees as they benefit from a strengthened labor market.”

Rick Hermanns, HireQuest’s President and Chief Executive Officer

“We believe the improving demand environment we have seen throughout 2026 positions our franchisees well as we close out the year and look ahead to 2027. We have a strong balance sheet and ample liquidity, and we remain focused on disciplined capital allocation as we work to deliver consistently profitable results and enhanced value for our shareholders.”

Rick Hermanns, HireQuest’s President and Chief Executive Officer
4:07 PM ET 8-K
Financial Results Solesence, Inc. SLSN

Solesence Financial Results

Solésence reported record third quarter 2026 financial results, with revenue increasing 38% year-over-year to $20.2 million. The company achieved its highest-ever quarterly net income of $3.7 million, driven by operational excellence and strong demand from brand partners.

Term
Q3 2026

“We’re very pleased that Solésence delivered solid top line growth as well as steady operational and strategic progress in the third quarter, driven by key milestones across our Transform and Transcend framework. Most notably, we reached a major turning point by completing the primary investment and implementation phase of our first pillar, operational excellence. This elevated capacity and efficiency position us to meet robust demand from our brand partners today while seamlessly scaling for tomorrow. Paired with our continued innovation in novel formulations and expanding global presence, Solésence is uniquely positioned to deliver long-term, profitable growth and lead the market in meeting evolving consumer needs.”

Kevin Cureton, President and CEO

“By pairing record revenue and net income with strong margin expansion, we have positioned Solésence for sustained growth. The operational and financial improvements achieved throughout 2026 provide a strong foundation as we look ahead to 2027.”

Laura Riffner, Chief Financial Officer
4:07 PM ET 8-K
Financial Results ADARx Pharmaceuticals, Inc. ADRX

ADARx Pharmaceuticals Financial Results

ADARx Pharmaceuticals reported Q3 2026 financial results, highlighting a cash position of $611.8 million following its IPO and concurrent private placement with AbbVie. The company is advancing three Phase 2 clinical trials for agazisiran and received FDA Fast Track designation for onvuzosiran in hereditary angioedema.

“We have made significant progress across our pipeline of next-generation siRNA therapeutics, bolstered by the successful completion of our IPO and concurrent private placement. These financings provide the resources to advance three clinical-stage programs in parallel, bring two advanced preclinical candidates into the clinic, and support additional IND filings as we expand our pipeline.”

Zhen Li, Ph.D., President and Chief Executive Officer of ADARx

“As the siRNA field evolves, we see tremendous opportunity to expand the range of diseases these therapeutics can address. We believe that our progress with differentiated liver-targeted programs and targeted delivery to extrahepatic tissues positions us to advance our mission of delivering life-changing treatments to patients with unmet medical needs.”

Zhen Li, Ph.D., President and Chief Executive Officer of ADARx
4:07 PM ET 10-Q
Financial Results Immix Biopharma, Inc. IMMX

Immix Biopharma Q3 2026 Results: Net Loss of $13.9M, Loss Widens

Immix Biopharma, Inc. reported a significant increase in cash and cash equivalents to $320.3 million as of September 30, 2026, compared to $93.9 million at year-end 2025. The company's accumulated deficit grew to $140.0 million, driven by nine-month operating expenses including $22.4 million in general and administrative costs and $16.9 million in research and development.

Key figure
Net loss $13.9M
4:07 PM ET 8-K
Financial Results Digimarc Corp DMRC

Digimarc Financial Results

Digimarc reported third quarter 2026 financial results, with total revenue of $6.4 million and a net loss of $8.1 million. The company noted that momentum is building with new customers in retail and CPG, though ARR decreased to $10.8 million primarily due to the expiration and step-down of two major commercial contracts.

“Last quarter we said our new execution focus was starting to show results. Since then, many of those results moved from pipeline to signed business earlier than expected, with new customers committing to our solutions across retail and CPG.”

Paul Carreiro, Digimarc CEO

“Our commercial leadership team is mostly in place, and our focus is clear: turn this momentum into recurring and predictable revenue growth in 2027.”

Paul Carreiro, Digimarc CEO
4:07 PM ET 8-K
Financial Results Newsmax Inc. NMAX

Newsmax Financial Results

Newsmax reported record Q3 2026 revenue of $69.0 million, a 52.5% year-over-year increase, driven by strong affiliate fees and a $14 million service revenue termination fee. The company achieved net income of $15.2 million and Adjusted EBITDA of $19.0 million, marking its second consecutive profitable quarter. Additionally, the company announced the resignation of director Nancy G. Brinker and the appointment of Carla Sands to the Board.

Term
Q3 2026

“The third quarter was the strongest in our history as a public company. Setting aside the one-time revenue item, we delivered our fastest revenue growth since our listing and a second consecutive profitable quarter.”

Christopher Ruddy, Chief Executive Officer of Newsmax

“Our third quarter results reflect the operating leverage we are building across the business, with affiliate and licensing growth continuing to shift our revenue mix toward our highest-margin streams.”

Darryle Burnham, Chief Financial Officer of Newsmax
4:07 PM ET 8-K
Financial Results OpenWorld, Inc. OPNW

OpenWorld Financial Results

OpenWorld, Inc. reported its first quarterly results as a Nasdaq-listed company following its reverse takeover of VerifyMe. The company reported revenue of $7.4 million and a GAAP net loss of $10.2 million, highlighting a strategic shift toward high-margin real-world asset (RWA) tokenization which contributed $6.4 million to the quarterly revenue.

Term
Q3 2026

“Q3 2026 was a defining quarter as we completed our transition to the public markets and accelerated our evolution into a high-margin RWA platform and major deal-origination company.”

Matthew Shaw, Chairman and Chief Executive Officer

“Revenue from our RWA business grew from zero a year ago to more than $6 million in the 2026 third quarter and $9 million for the first nine months of the year, while we maintained exceptional gross margins of more than 80%.”

Matthew Shaw, Chairman and Chief Executive Officer
4:07 PM ET 8-K
Financial Results Journey Medical Corp DERM

Journey Medical Financial Results

Journey Medical Corporation reported third quarter 2026 financial results, featuring total revenues of $19.0 million, an 8% increase year-over-year. Growth was primarily driven by its oral rosacea treatment, Emrosi, which saw an 84% revenue increase to $9.0 million. The company's net loss narrowed to $1.3 million compared to $2.3 million in the prior-year period.

“We continued to make progress during the third quarter, delivering year-over-year revenue growth, a higher gross margin, and positive EBITDA. Third quarter sales of Emrosi®, our best-in-class oral rosacea treatment, increased by 84% compared to the prior-year period, driven by growth in prescription demand and continued improvement in the mix of prescriptions reimbursed by health plans.”

Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer

“Building on this progress and with over $22 million in cash, we believe we are well-positioned to advance our mission of delivering value to our dermatology customers and their patients while building long-term shareholder value.”

Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer
4:07 PM ET 10-Q
Financial Results Fennec Pharmaceuticals Inc. FENC

Fennec Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $4.64M

Fennec Pharmaceuticals reported a significant increase in total revenue to $19.6 million for Q3 2026, driven by PEDMARK product sales. The company achieved net income of $4.6 million compared to a net loss in the prior year, supported by a decrease in G&A expenses and improved operating margins. Cash reserves stood at $48.7 million, which management expects will be sufficient to fund operations based on the current plan.

Key figure
Net income $4.64M
4:07 PM ET 10-Q
Financial Results Elite Pharmaceuticals Inc ELTP

Elite Pharmaceuticals Q2 2026 Results: Net Income $17.3M, Up 26.4% YoY

Elite Pharmaceuticals reported net income of $23.2 million for the six months ended September 30, 2026, a significant increase from $7.8 million in the prior year period, largely driven by a $9.8 million gain from the change in fair value of derivative warrants. While six-month revenue slightly decreased to $72.4 million, the company maintained a strong cash position of $34.9 million and significantly reduced its total liabilities from $39.4 million to $22.1 million.

Key figure
Net income $17.3M · +26.4% YoY
4:07 PM ET 10-Q
Financial Results Nuwellis, Inc. NUWE

Nuwellis Q3 2026 Results: Net Loss of $1.97M

Nuwellis, Inc. reported net sales of $6.58 million for the nine months ended September 30, 2026, a 12.6% increase over the prior year. Despite improved gross margins, the company incurred a net loss of $11.34 million, driven by higher operating expenses and significant financing-related costs, though this was an improvement from the $15.10 million loss in the same period of 2025.

Key figure
Net loss $1.97M
4:07 PM ET 10-Q
Financial Results Jerash Holdings (US), Inc. JRSH

Jerash Holdings Q2 2026 Results: Net Income $2.16M, Up 367.3% YoY

Jerash Holdings reported a significant increase in net income to $3.84 million for the six months ended September 30, 2026, compared to $0.80 million in the prior year period, driven by a 23% revenue growth to $100.5 million. The company maintained its quarterly dividend of $0.05 per share while seeing a substantial improvement in cash flow from operating activities, which rose to $7.53 million.

Key figure
Net income $2.16M · +367.3% YoY
4:07 PM ET 8-K
Financial Results Prime Medicine, Inc. PRME

Prime Medicine Financial Results

Prime Medicine reported Q3 2026 financial results, highlighting the first patient dosed in its Phase 1/2 trial for Wilson disease and FDA clearance for its AATD program. The company also completed a $143.7 million public offering, extending its cash runway through 2027.

Term
Q3 2026

“Prime Medicine continued to make significant progress this quarter, highlighted by dosing the first patient in our Phase 1/2 trial of PM577a for Wilson disease, our first clinical study of an in vivo Prime Editing therapy.”

Allan Reine, M.D., Chief Executive Officer

“Our recent financing strengthens our balance sheet and provides additional resources needed to advance these programs through key clinical milestones. Looking ahead, we expect 2027 to be a meaningful year for the patient communities we hope to treat, with initial clinical data anticipated from both PM577a and PM647 and a planned BLA submission for PM359.”

Allan Reine, M.D., Chief Executive Officer
4:07 PM ET 8-K
Financial Results Jefferson Capital, Inc. JCAP

Jefferson Capital Financial Results

Jefferson Capital reported record third-quarter 2026 results, with revenue climbing 23% to $185.5 million and net income reaching $46.9 million. The company saw significant growth in deployments, which rose 111% to $318.0 million, driven by triple-digit growth across its U.S., U.K., and Latin American platforms.

Term
Q3 2026

“Third quarter performance was excellent and we continue to build significant momentum in all key aspects of the business. We are confident in our ability to generate attractive shareholder returns in the near and long term.”

David Burton, Chairman and Chief Executive Officer

“We delivered the largest third quarter deployments in the Company’s history, with triple digit growth year-over-year in the United States, the United Kingdom and Latin America – a testament to our leadership position in hard-to-value and hard-to-service asset classes, the growing geographic breadth of our platform, and the strength of our client relationships.”

David Burton, Chairman and Chief Executive Officer
4:07 PM ET 8-K
Financial Results System1, Inc. SST

System1 Financial Results

System1 reported Q3 2026 revenue of $26.0 million and a GAAP net loss of $61.5 million, citing traffic and monetization headwinds from Google's AI overviews. Concurrent with the results, the company announced its intention to voluntarily delist its Class A common stock from the NYSE and transition to the OTC Venture Market to reduce costs.

“Our third quarter was challenging, as Google's AI overviews continued to siphon traffic from publishers and Google reduced monetization for independent search engines. We responded with a comprehensive strategic review of our businesses and a reallocation of resources to our offerings where AI is a tailwind. Our decision to move from the NYSE to the OTC Venture Market comes from the same discipline – lowering our costs and freeing our team to focus on growth initiatives.”

Michael Blend, System1’s Co-Founder & Chief Executive Officer

“Our third quarter results reflect continued pressure on Google monetization at Startpage and the loss of monetizable organic traffic to CouponFollow driven by Google displacing organic links with AI overviews on its search results pages. Our priority is maximizing cash flow and preserving liquidity while we invest selectively behind our highest-return opportunities.”

Tridivesh Kidambi, Chief Financial Officer of System1
4:07 PM ET 8-K
Financial Results Intrusion Inc INTZ

Intrusion Financial Results

Intrusion Inc. reported Q3 2026 revenue of $2.7 million, an 84% sequential increase driven by the first full quarter of contribution from the VigilAigent acquisition. The company implemented cost-reduction initiatives and completed a $4.0 million debt-for-equity exchange in October to improve its balance sheet and Nasdaq compliance status.

Term
Q3 2026

“Our third quarter results represent an important step forward for Intrusion as we continued to stabilize our business, integrate VigilAigent’s capabilities with our existing platform, and execute on our growth strategy.”

Tony Scott, President & Chief Executive Officer

“Our focus remains on growing recurring revenue, expanding our commercial reach, and continuing to build a stronger platform that delivers AI-driven cybersecurity solutions to address the evolving threats facing our customers across both commercial and government markets.”

Tony Scott, President & Chief Executive Officer
4:07 PM ET 10-Q
Financial Results Fractyl Health, Inc. GUTS

Fractyl Health Q3 2026 Results: Net Loss of $14.2M, Loss Narrows

Fractyl Health reported a net loss of $30.5 million for the first nine months of 2026, a significant improvement from the $97.2 million loss in the prior year period, primarily driven by a $29.1 million gain from the change in fair value of warrant liabilities. The company implemented a strategic reprioritization in October 2026, including a workforce reduction, to extend its financial runway as cash and cash equivalents decreased to $31.5 million from $81.5 million at year-end 2025.

Key figure
Net loss $14.2M
4:07 PM ET 10-Q
Financial Results Pershing Square Sparc Holdings, Ltd.

Pershing Square Sparc Holdings Q3 2026 Results: Net Loss of $1.86M, Loss Widens

Pershing Square SPARC Holdings, Ltd. reported a net loss of $1.86 million for the quarter ended September 30, 2026, primarily driven by legal fees and a $1.77 million change in the fair value of Sponsor Warrants liability. The company remains a shell company focused on identifying a business combination, with $19.26 million in total cash and cash equivalents as of the period end.

Key figure
Net loss $1.86M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.